{"id":1249,"date":"2011-08-08T12:37:14","date_gmt":"2011-08-08T16:37:14","guid":{"rendered":"http:\/\/jamie.workingagenda.com\/blog\/?p=1249"},"modified":"2018-10-22T12:30:40","modified_gmt":"2018-10-22T16:30:40","slug":"market-cap-per-employee-and-rate-of-rd-spending-for-large-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/jamie.workingagenda.com\/blog\/2011\/08\/08\/market-cap-per-employee-and-rate-of-rd-spending-for-large-pharmaceutical-companies\/","title":{"rendered":"Market cap per employee, and rate of R&D spending, for large pharmaceutical companies"},"content":{"rendered":"<\/abbr>\n

Among large bio-pharmaceutical firms, Gilead is an outlier <\/a>in terms of market cap per employee.<\/p>\n

\"\"<\/a><\/p>\n

The data is also presented in the table below. <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Firm<\/strong><\/td>\nR&D spending as percent of 2011 2nd quarter revenue<\/strong><\/td>\n Market Cap, billions of USD (August 7, 2011)<\/strong> <\/td>\nNumber of Employees<\/strong><\/td>\nMrk Cap \/employees<\/strong> <\/td>\n<\/tr>\n
Johnson & Johnson<\/td>\n11.3%<\/td>\n $  171.90 <\/td>\n115,000<\/td>\n $   1,494,783 <\/td>\n<\/tr>\n
Roche<\/td>\n17.9%<\/td>\n $  146.50 <\/td>\n80,653<\/td>\n $   1,816,423 <\/td>\n<\/tr>\n
Novartis<\/td>\n16.1%<\/td>\n $  131.16 <\/td>\n119,418<\/td>\n $   1,098,327 <\/td>\n<\/tr>\n
Pfizer<\/td>\n13.2%<\/td>\n $  138.19 <\/td>\n110,600<\/td>\n $   1,249,458 <\/td>\n<\/tr>\n
Merck<\/td>\n15.9%<\/td>\n $  97.88 <\/td>\n91,000<\/td>\n $   1,075,604 <\/td>\n<\/tr>\n
Sanofi<\/td>\n14.3%<\/td>\n $  95.99 <\/td>\n101,575<\/td>\n $    945,016 <\/td>\n<\/tr>\n
Abbott<\/td>\n10.8%<\/td>\n $  77.74 <\/td>\n90,000<\/td>\n $    863,778 <\/td>\n<\/tr>\n
AstraZeneca<\/td>\n12.9%<\/td>\n $  60.22 <\/td>\n61,100<\/td>\n $    985,597 <\/td>\n<\/tr>\n
Amgen<\/td>\n21.0%<\/td>\n $ 48.16 <\/td>\n17,100<\/td>\n $   2,816,374 <\/td>\n<\/tr>\n
BMS<\/td>\n17.0%<\/td>\n $ 46.79 <\/td>\n27,000<\/td>\n $   1,732,963 <\/td>\n<\/tr>\n
Lilly<\/td>\n20.2%<\/td>\n $  41.95 <\/td>\n38,065<\/td>\n $   1,102,062 <\/td>\n<\/tr>\n
Gilead<\/td>\n13.2%<\/td>\n $  29.32 <\/td>\n4,000<\/td>\n $   7,330,000 <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Among large bio-pharmaceutical firms, Gilead is an outlier in terms of market cap per employee.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[80,7],"tags":[],"_links":{"self":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/1249"}],"collection":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/comments?post=1249"}],"version-history":[{"count":9,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/1249\/revisions"}],"predecessor-version":[{"id":1483,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/1249\/revisions\/1483"}],"wp:attachment":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/media?parent=1249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/categories?post=1249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/tags?post=1249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}